States eye their own coverage requirements if individual mandate is repealed

If Republicans pass their tax cut plan as expected, including a repeal of the Affordable Care Act (ACA)’s individual mandate, Democratic-leaning states may respond with laws requiring their residents to buy health insurance or face a tax penalty.

POLITICO reports California, Connecticut, Maryland and New Jersey are among the states considering state-level mandate replacements to encourage younger, healthier customers to remain in the individual market risk pool. States that run their own insurance exchanges would be more likely to tackle the issue, despite the political risk in pursuing an unpopular requirement in an election year.

“If you get rid of the individual mandate, it’s bad for everything,” said Connecticut Lt. Gov. Nancy Wyman, a Democrat who chairs the board of the state’s exchange.

Before the ACA, other states had tried implementing ACA-like requirements, such as banning insurers from denying coverage based on pre-existing conditions, without a coverage mandate. In the case of New York and Washington, the result was a “death spiral” and rapid exit of insurers from the individual market. On a national scale, however, the Congressional Budget Office has said the exchanges would be stable without the mandate.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.